22 March 2017 - Recommendation states price needs to be reduced by 90%.

The CADTH Canadian Drug Expert Committee has recommended that reslizumab be reimbursed for add-on maintenance treatment of adult patients with severe eosinophilic asthma who are inadequately controlled with medium- to high-dose inhaled corticosteroids and an additional asthma controller(s) (e.g., a long-acting beta-agonist), and have a blood eosinophil count of ≥ 400 cells/μL at initiation of the treatment, if the following clinical criteria and both conditions are met:

• Patients who have experienced one or more clinically significant asthma exacerbations in the past 12 months, who have an Asthma Control Questionnaire 7 score ≥ 1.5 points, and who show reversibility (at least 12% and 200 mL) on pulmonary function tests (i.e., spirometry)
  
• Reslizumab is not to be used in combination with other biologics for the treatment of asthma
  

Read CADTH outcome for reslizumab